MedTrace Logo

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

NCT04982276 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2025-11-19

No results posted yet for this study

Summary

This is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .

Conditions

  • Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

paclitaxel

Subjects will receive AK104 and AK109 in combination with paclitaxel.

BIOLOGICAL

AK104

Subjects will receive AK104 by intravenous administration.

BIOLOGICAL

AK109

Subjects will receive AK109 by intravenous administration.

DRUG

paclitaxel

Subjects will receive AK109 in combination with paclitaxel.

Sponsors & Collaborators

Principal Investigators

  • Lin Shen, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2025-12-30
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982276 on ClinicalTrials.gov